Open AccessClinical and Economic Impact of Glatiramer Acetate Versus Beta Interferon Therapy Among Patients With Multiple Sclerosis in a Managed Care Population
Author(s) -
Daniel A. Ollendorf,
Evguenia Jilinskaia,
MerriKay Oleen-Burkey
Publication year - 2002
Publication title -
journal of managed care pharmacy
Language(s) - English
Resource type - Journals
eISSN - 1944-706X
pISSN - 1083-4087
DOI - 10.18553/jmcp.2002.8.6.469
Subject(s) - medicine , glatiramer acetate , incidence (geometry) , population , hazard ratio , retrospective cohort study , multiple sclerosis , managed care , cohort , confounding , ambulatory , health care , disease , confidence interval , immunology , economic growth , physics , optics , economics , environmental health
To examine the outcomes of use of glatiramer acetate (GA) versus beta interferons-1a (intramuscular) (1A) and -1b (1B) in patients with multiple sclerosis (MS) in a managed care setting.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom